活动首页 >日程安排

特别讨论专场 | 监管科学以促进医药创新

时间: 05 月 21 日 16:00 - 16:45
内容介绍:

监管科学作为一个名词,大约出现在上个世纪七十年代,如今它已经成为医药监管领域里最常用的词汇之一。各国的监管机构对它有相似的定义和解读。例如,FDA 将监管科学定义为“开发新工具,新标准和新方法以评估受FDA监管产品的安全性,有效性,质量和性能的科学“。EMA 将监管科学归纳为“评估医药产品在生命周期中的质量,安全性,和有效性的多个学科的总合”。


2018年度是医药创新的标志之年。去年美国FDA批准上市的新药数量达到历史最高 - 59 个新分子实体 (NME)。其中有一半以上是孤儿药, 用于治疗一系列有未满足医疗需求的罕见病。


近年来随着科技的加速发展,在医疗领域,越来越多创新, 复杂的药物被研发出来。这些创新药物,包括但不限于,免疫治疗,基因治疗,细胞治疗,和组织工程医学,它们代表了医疗保健的未来。


在科技进步日新月异的今天,监管机构必须不断提升监管科学的水准:不仅要跟上生物医学加速创新的步伐,还要有前瞻性地促进创新技术向医药产品的转化。


在讨论部分,每个监管机构的代表将解释其机构应对当前监管挑战而采取的新政策,分享他/她对其监管机构有关监管科学战略计划的见解,以及如何扩大/深化各机构之间的合作, (如果时间许可)讨论在平衡鼓励创新与致力让患者获得新药的挑战。


讨论主要议题:

- 各国监管机构新政下的创新治疗策略

- 生物类似药的法规及影响

- 新兴国家的ICH发展进展

- 各国监管面临的最大挑战


特邀讨论嘉宾:

佐藤淳子 博士

日本PMDA国际项目办公室主任


Leigh VERBOIS 博士

美国FDA全球政策与战略办公室,全球运行办公室主任


Agnes SAINT-RAYMOND 医学博士

EMA国际事务及Portfolio Board负责人


何如意 医学博士

清华大学医学院教授

清华大学医学院医药监管科学研究中心学术委员会主任

国投创新医药健康首席科学家


日程嘉宾
2019 DIA中国年会/ 2019 DIA China Annual Meeting
佐藤淳子
日本PMDA国际项目办公室主任
Dr. Junko Sato is an Office Director of Office of International Program at Pharmaceuticals and Medical Devices Agency (PMDA). She joined Regulatory Agency in 1998. She became a review director of Office of New Drug in 2004 and moved to Office of Safety in 2009 to develop a new risk management system through life cycle of drugs. During the period, she visited U.S.FDA as a guest reviewer from September 2002 to March 2003. From May 2012 to April 2014, she was dispatched to EMA as MHLW/PMDA Liaison. She enhanced collaboration between EMA and MHLW/PMDA and brought a huge success as the liaison. She contributed to some global harmonization activities, for example, ICH, CIOMS etc. She also contributes many DIA activities. She received DIA Outstanding Service Award 2010. She led the activities of PMDA Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs (PMDA-ATC) including planning/conduct of all the trainings, and contributes to building stronger bilateral relationship with ASEAN countries by playing the role as the contact point. She also works for AMR project like EMA-FDA-PMDA tripartite meeting to discuss convergence on approaches for the evaluation of antibacterial drugs. She is an Infection Control Doctor certificated by The Japanese Association of Infectious Disease.
2019 DIA中国年会/ 2019 DIA China Annual Meeting
Agnes Saint-Raymond
EMA国际事务及Portfolio Board负责人
Head of International Affairs (ad interim), Head of Portfolio Board MD and qualified Paediatrician. Chef de Clinique in Paed. in Necker-Enfants-Malades Hospital (Paris, 1985-1990). Joined French Agency for medicines (now ANSM) in 1995 as Head of a Pharmaco-Toxico-Clinical Assessment Unit. Joined EMA in 2000. Head of Special Areas for Human Medicines (Paediatric Medicines, Orphan Medicines, Scientific Advice, SME Office, and Scientific Support & Projects) until 2013. Head of Portfolio Board since Aug 2013. Head of International Affairs (a.i.) since Nov 2016.